Pulsatile dosing vs sustained signalling
also: pulsatile vs continuous dosing, pulsatile GH secretion, receptor downregulation dosing, no-DAC vs DAC
The contrast between intermittent receptor stimulation mimicking physiological hormone pulses and continuous receptor activation, which often leads to receptor downregulation and signal attenuation.
In endocrinology, pulsatile dosing refers to administering a signal in discrete, short-lived bursts that mimic the episodic secretion patterns of endogenous hormones. Sustained or continuous signalling, by contrast, maintains persistent receptor occupancy. The distinction matters enormously for receptor-coupled systems because many G protein-coupled receptors (GPCRs) adapt to prolonged stimulation through desensitisation and downregulation — reducing or eliminating the cellular response despite continued ligand presence.
Why it matters in peptide research
Growth hormone (GH) secretion is inherently pulsatile: deep sleep triggers large GH pulses, with relative quiescence between peaks. The somatotroph cells of the pituitary are exquisitely sensitive to this pulsatile pattern; they respond to each GHRH pulse with a burst of GH release and then reset during the low-GHRH inter-pulse trough. When GHRH receptor occupancy is maintained continuously — as occurs with long-acting GHRH analogues using drug affinity complex (DAC) technology — the pituitary somatotrophs downregulate their GHRH receptors and the GH response progressively attenuates.
This is precisely the research rationale behind preferring CJC-1295 without DAC (also called MOD-GRF 1-29) over CJC-1295 with DAC in many protocols. The no-DAC version has a half-life of approximately 30 minutes, producing a short pulse of GHRH receptor stimulation that mimics the natural hypothalamic signal and then clears before the next administration. The DAC version's multi-day half-life means near-continuous GHRH receptor occupancy, which laboratory data suggest leads to GH axis blunting over time despite an initial somatotroph stimulation advantage.
The same principle applies to GnRH — a classic teaching example. Native GnRH administered pulsatile stimulates LH and FSH release; the same GnRH administered as a continuous infusion or as a long-acting agonist depot (leuprolide, triptorelin) ultimately suppresses LH and FSH through receptor downregulation — the basis of medical castration. Understanding pulsatility as a physiological information-encoding mechanism, not just a dosing convenience, is fundamental to rational peptide protocol design.
Peptides / stacks that act on this
- CJC-1295 — GHRH analogue available in both no-DAC (short-acting, pulsatile-mimicking) and DAC (long-acting, sustained) forms; illustrates the practical consequences of pulsatile vs sustained GHRH receptor stimulation
Reading tip
When evaluating a peptide protocol, always ask whether the target receptor is a GPCR and whether the endogenous signal for that receptor is pulsatile. If yes, a dosing schedule that mimics physiological inter-pulse troughs will generally maintain receptor sensitivity better than one that sustains ligand exposure.